May 10, 2018 - Halozyme Therapeutics, Inc. (NASDAQ:HALO) has filed a financial statement reporting Payments To Acquire Available For Sale Securities of $114,661,000 USD. Previously, on May 09, 2017, Halozyme Therapeutics, Inc. reported Payments To Acquire Available For Sale Securities of $54,830,000 USD. This represents a change of 109.12% in Payments To Acquire Available For Sale Securities.

Period EndPeriodValue
2018-03-31 2018-Q1 114,661,000
2017-03-31 2017-Q1 54,830,000
2016-03-31 2016-Q1 126,431,000
2015-03-31 2015-Q1 33,185,000
2014-03-31 2014-Q1 65,005,000
2013-03-31 2013-Q1 48,947,000
AccruedOutsourcedResearchAndDevelopmentExpensesCurrent AccruedOutsourcedResearchandDevelopmentExpensesLongTerm Accruedmanufacturingexpenses AllocatedShareBasedCompensationExpense CostsAndExpenses CurrentFederalTaxExpenseBenefit CurrentStateAndLocalTaxExpenseBenefit DeferredFederalIncomeTaxExpenseBenefit DeferredForeignIncomeTaxExpenseBenefit DeferredRevenue DeferredRevenueCurrent DeferredRevenueNoncurrent DeferredRevenueRelatingToUpfrontPaymentLicenseFees DeferredStateAndLocalIncomeTaxExpenseBenefit DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost HypotheticalLicenseRevenueunderASC606 HypotheticalRoyaltyRevenueunderASC606 IncomeTaxExpenseBenefit IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate IncomeTaxReconciliationNondeductibleExpenseOther IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost IncreaseDecreaseInDeferredRevenue IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets InterestExpense LicenseAndServicesRevenue OperatingLeasesRentExpenseNet OtherNoncashExpense OtherNonoperatingIncomeExpense OtherPrepaidExpenseCurrent PrepaidExpenseAndOtherAssets PrepaidExpenseAndOtherAssetsCurrent PrepaidExpenseAndOtherAssetsNoncurrent PrepaidExpenseCurrent RecognitionOfDeferredRevenue ResearchAndDevelopmentExpense Revenueamortizationoflicensepayments Revenues RoyaltyRevenue SalesRevenueGoodsNet SellingGeneralAndAdministrativeExpense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense ValuationAllowancesAndReservesChargedToCostAndExpense

Related News Stories

Top Analyst Upgrades and Downgrades: Aetna, Analog Devices, Lowe’s, Merck, Pfizer, Plug Power, Qualcomm, Target and More

2018-08-23 247wallst
Stocks were indicated to open lower on Thursday morning, though the S&P 500 hit an all-time high earlier in the week. Earnings season is all but over now and was quite strong, with more than 70% of the companies exceeding expectations. Despite the gains in the market, 2018 has been choppy, and investors have seen less reward in buying every dip than they had been used to in recent years. Many investors also are trying to decide how they want their investments positioned ahead of the midterm elections and given international trade concerns. (44-1)

A Glimpse into the Pancreatic Cancer Pipeline

2018-08-23 biospace
The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7. (0-1)

Halozyme: A Look At The Q2 2018 Earnings

2018-08-19 seekingalpha
Halozyme Therapeutics (NASDAQ:HALO) is a robust grower that is operating near its growth inflection. Most investment risks are now significantly deleveraged due to the increasing sales from the approved molecules. Despite that that the partnered products in commercialization are delivering meaningful sales, there are substantial unlocked values in the developing pipeline. In the past 52-week, the stock traded up by $4.

Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good day, ladies and gentlemen and welcome to the Halozyme Investor Call. We now have all of have speakers in conference. Please be aware that your line is in listen-only mode. At the conclusion on today’s presentation, we will open the floor for questions, [Operator Instructions]. (4-0)

CUSIP: 40637H109